Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc. Common Stock
Your view on SPTX
Overview
What the company does, where it operates, and who runs it.
About Seaport Therapeutics, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Daphne Zohar
- Headquarters
- 101 Seaport Blvd., Boston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Daphne Zohar
- Headquarters
- 101 Seaport Blvd., Boston, MA, US
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology.
This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions.
Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications.
Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Seaport Therapeutics, Inc. Common Stock, and the rating behind it. SPTX last traded at $17.93; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Seaport Therapeutics, Inc. Common Stock. Starting points for Seaport Therapeutics, Inc. Common Stock: EPS -$1.64, beta 1.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Seaport Therapeutics, Inc. Common Stock. Seaport Therapeutics, Inc. Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Seaport Therapeutics, Inc. Common Stock. Trailing twelve-month EPS for Seaport Therapeutics, Inc. Common Stock stands at -$1.64. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Seaport Therapeutics, Inc. Common Stock. Seaport Therapeutics, Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Seaport Therapeutics, Inc. Common Stock valued side by side against its closest peers. Seaport Therapeutics, Inc. Common Stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Seaport Therapeutics, Inc. Common Stock, and how their positions are changing. At a $959.8M market value, institutional positions materially move Seaport Therapeutics, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Seaport Therapeutics, Inc. Common Stock executives and directors. Shares of Seaport Therapeutics, Inc. Common Stock have traded between $14.85 and $24.48 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Seaport Therapeutics, Inc. Common Stock. Seaport Therapeutics, Inc. Common Stock is a $959.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Seaport Therapeutics, Inc. Common Stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Seaport Therapeutics, Inc. Common Stock. Coverage tracks Seaport Therapeutics, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.